SynchroPET is a biotechnology innovator that is revolutionizing the field of PET imaging with its advanced technology. Developed at Brookhaven National Laboratory, their patented imaging products offer researchers and clinicians unparalleled insight into drug discovery, pre-clinical imaging, and clinical assessment. With the potential to shorten drug discovery times, enhance diagnostic capabilities, and provide quantitative functional imaging, SynchroPET is paving the way for new opportunities in PET MRI imaging.
Offering services such as the Arterial PET Scanner and Mini-PET, SynchroPET's devices are currently used for research purposes only and have not yet been evaluated by the FDA. The Arterial PET Scanner provides a quantitative tool for accelerating chemotherapy assessment, while the Mini-PET offers simultaneous PET MRI capabilities and can be easily transported within the laboratory. With a focus on advancing research and clinical assessment, SynchroPET is at the forefront of innovation in the field of PET imaging.
Generated from the website